Shanu Modi
MD
Medical Oncologist, Breast Cancer Program
👥Biography 个人简介
Shanu Modi is the lead investigator of the landmark DESTINY-Breast04 trial, which established trastuzumab deruxtecan (T-DXd) as a practice-changing therapy for HER2-low metastatic breast cancer (IHC 1+ or 2+/ISH-), demonstrating a 49% reduction in risk of progression or death versus standard chemotherapy. Her work has fundamentally redefined HER2-low as an actionable biomarker category distinct from HER2-zero. She is a world authority on ADC development in breast cancer and leads multiple studies exploring T-DXd in earlier settings and novel combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Shanu Modi 的研究动态
Follow Shanu Modi's research updates
留下邮箱，当我们发布与 Shanu Modi（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment